Policy
Rare eye condition prompts new FDA warning on popular GLP-1 drugs
The Brief
- The FDA is requiring makers of GLP-1 drugs such as Ozempic and Wegovy to add a warning about a rare eye condition.
- The condition can cause vision loss.
- The requirement was reported by Medical Xpress on 2026-11-10.
Why it matters
Clinicians and patients using GLP-1 drugs will see a new labeled warning about a rare cause of vision loss, which may affect how these drugs are prescribed and monitored.
Who’s affected
- patients taking GLP-1 drugs such as Ozempic or Wegovy
- clinicians prescribing GLP-1 medications
- #glp-1
- #fda
- #drug safety
- #eye health
- #regulation
The U.S. Food and Drug Administration (FDA) is requiring makers of Ozempic, Wegovy and similar drugs to warn of a rare eye condition that can cause vision loss.
Timeline
Medical Xpress reports that the FDA is requiring GLP-1 drug makers to warn of a rare eye condition
Medical Xpress - latest medical and health news stories
Rare eye condition prompts new FDA warning on popular GLP-1 drugs